Evidence map›Paper›PMID 23521696›Full record

ArticleImmunology2013

Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Wen Yang, Yan Song, Yun-Long Lu, Jun-Zhong Sun, Hong-Wei Wang

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04230954 (A Phase II Study of Cabozantinib), which is not on this map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04230954 phase2terminatednot on this mapstarted 2020, after this paper: background citation

A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

TypeinterventionalSponsorUniversity of South AlabamaRan2020 to 2022Enrolled5ConditionsCervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer, Persistent Cervical CancerArmsCabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Expression of HPV-16 E6 and E7 oncoproteins altersFrontiers in cellular and infection microbiology · 2023
    Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wen YangDepartment of Gynaecology and Obstetrics, Chinese PLA (People's Liberation Army) General Hospital, Beijing, China.
Yan Song
Yun-Long Lu
Jun-Zhong Sun
Hong-Wei Wang
First Affiliated Hospital of Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impaired local cellular immunity contributes to the pathogenesis of persistent high-risk human papillomavirus (HR-HPV) infection and related cervical intraepithelial neoplasia (CIN), but the underlying molecular mechanisms remain unclear. Recently, the programmed death 1/programmed death 1 ligand (PD-1/PD-L1; CD279/CD274) pathway was demonstrated to play a critical role in attenuating T-cell responses and promoting T-cell tolerance during chronic viral infections. In this study, we examined the expression of PD-1 and PD-L1 on cervical T cells and dendritic cells (DCs), respectively, from 40 women who were HR-HPV-negative (-) or HR-HPV-positive (+) with CIN grades 0, I and II-III. We also measured interferon-γ, interleukin-12 (IL-12) and IL-10 in cervical exudates. The most common HPV type was HPV 16, followed by HPV 18, 33, 51 and 58. PD-1 and PD-L1 expression on cervical T cells and DCs, respectively, was associated with HR-HPV positivity and increased in parallel with increasing CIN grade. The opposite pattern was observed for CD80 and CD86 expression on DCs, which decreased in HR-HPV+ patients in parallel with increasing CIN grade. Similarly, reduced levels of the T helper type 1 cytokines interferon-γ and IL-12 and increased levels of the T helper type 2 cytokine IL-10 in cervical exudates correlated with HR-HPV positivity and CIN grade. Our results suggest that up-regulation of the inhibitory PD-1/PD-L1 pathway may negatively regulate cervical cell-mediated immunity to HPV and contribute to the progression of HR-HPV-related CIN. These results may aid in the development of PD-1/PD-L1 pathway-based strategies for immunotherapy of HR-HPV-related CIN.

Indexed as

Immunity, CellularAdultB7-1 AntigenB7-2 AntigenB7-H1 AntigenBiopsyCase-Control StudiesDendritic CellsEnzyme-Linked Immunosorbent AssayExudates and TransudatesFemaleFlow CytometryHuman Papillomavirus DNA TestsHumansInterferon-gammaInterleukin-10B7-1 AntigenB7-2 AntigenB7-H1 AntigenCD274 protein, humanCD86 protein, humanIFNG protein, humanIL10 protein, humanInterferon-gammaInterleukin-10Interleukin-12PDCD1 protein, humanProgrammed Cell Death 1 Receptorcervical intraepithelial neoplasiacytokineshuman papillomavirusprogrammed death-1programmed death-1 ligand

Identifiers

PMID23521696
PMCPMC3719068
OpenAlexW1986104642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.